Abstract: A blue electroluminescent compound and an organic electroluminescent device using the blue electroluminescent compound, which includes a 9,10-diphenyl anthracene unit in its backbone and has alkoxy groups and substituted or unsubstituted amino group introduced to the 2 and 5 positions on the phenyl group in the diphenyl anthracene unit.

Abstract: The present invention relates to red color emitting compounds for an organic electroluminescent device (OELD), particularly to red color emitting compounds represented by the following formula (1) having high luminescence efficiency and enhanced thermal-stability:

Abstract: A copy-protected optical medium comprising transient optical state change security materials that demonstrating an optical state change when exposed to the wavelengths of from about about 770 nm to about 830 nm.

Abstract: Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: 1

Abstract: The application concerns a compound of formula I: 1

Abstract: The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X=O, (CH2)m, S, SO, SO2, NH, NR8 or a chemical bond; Y=O, (CH2)m, S, SO, SO2, NH, NR8; Z=NH, O, NR8, S, SO, SO2. The remaining substituents are described in the specification.

Abstract: The present invention relates to compounds of the general formula (I) 1

Abstract: A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by formula (I) 1

Abstract: The present invention relates to new derivatives of amino acids and their use as medicaments.

Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.

Abstract: Compounds represented by general formula (I): and salts thereof, exhibiting excellent adenosine A3 receptor antagonism: wherein A is an optionally substituted benzene ring; B may be further substituted; and R1 is an optionally substituted cyclic group.

Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.

Abstract: The invention concerns novel N-(iminomethyl)amine derivatives comprising in their skeleton the aminophenylamine, oxodiphenylamine, carbazole, phenazine, phenoxazine or oxodiphenyl motif, their use as medicines and pharmaceutical compositions containing them. The invention concerns in particular the following compounds: -4-{[2-thienyl(imino)methyl]amino}-N-[2-(phenylamino)phenyl]-benzenebutanamide; -4-{[2-thienyl(imino)methyl]amino}-N-[4-(phenylamino)phenyl]-benzenebutanamide; -N-′[4-(10H-phenothiazin-2-yloxy)phenyl]-2-thiophenecarboximidamide; -4-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-(10H-phenothiazin-3-ylH)butanamide; -3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-(4-anilinophenyl)propanamide; -N′-(4-{2-[(10H-phenothiazin-3-ylmethyl)amino]ethyl}phenyl-2-thiophene carboximidamide.

Abstract: The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: A compound shown by the formula II, wherein Het is a mono- or polycyclic heterocyclic group comprising one or more hetero atoms selected from the group consisting of N, O and S which may be the same or different from each other; R1 is hydrogen, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; A is an optionally substituted lower alkylene, an optionally substituted lower alkenylene or a single bond; B is an optionally substituted imino or a single bond; or A and B taken together may form a single bond; and D is a single bond or a group of the formula (a):

Abstract: The present invention relates-to compounds of the general formula (I) 1

Abstract: A phenothiazine, acridan, acridone oxime, acridone hydrazone and dibenzodiazepine derivative represented by formula (I) 1

Abstract: Novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them.

Abstract: This invention relates to a novel, technically advantageous process for the preparation of a mixture of alkylated phenothiazines and diphenylamines. Starting from diphenylamine, this is reacted with elemental sulfur in the presence of iodine, and the substance mixture of diphenylamine and phenothiazine is treated with an olefin in the presence of an acid catalyst.

Abstract: The present invention relates to compounds of the general formula (I) 1

Abstract: The present invention relates to compounds of the general formula (I) 1

Abstract: The present invention relates-to compounds of the general formula (I) 1

Abstract: A process for preparation of alkylated diphenylamine antioxidant which comprises alkylating diphenylamine with a polyisobutylene in the presence of a clay catalyst, wherein the polyisobutylene has an average molecular weight in the range of 120 to 600 and wherein the polyisobutylene contains at least 25% methylvinylidene isomer.

Abstract: The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R5, Q, Z, Y, V, X and X′ are as defined herein.

Abstract: The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

Abstract: A reagent, kit and method for the quantative determination of ascorbic acid in a sample uses ascorbate oxidase which catalyzes the reaction of reduced ascorbic acid to oxidized ascorbic acid and hydrogen peroxide. Ascorbic acid in the sample is reacted with oxygen in the presence of the ascorbate oxidase, chromogen and peroxidase. Absorbance is determined and compared with a known calibration curve.

Abstract: N-demethylated and N,N-demethylated derivatives of toluidine blue O and compositions which include these derivatives and the conformational isomers of toluidine blue O. Improved methods for the detection of dysplastic oral tissue using such compositions.Processes for synthesis of toluidine blue O products, in which a complexing agent is introduced prior to the last stage of oxidation of a three-step synthesis from N,N-dimethyl-.rho.-phenylenediamine.An HPLC method for characterizing toluidine blue O products in which the mobile phase is an aqueous solution of an organic acid.

Abstract: The present invention relates to novel spherical agglomerates of 10-phenothiazinylpropanoic acid. The invention also relates to a process for obtaining those agglomerates.The process for preparing the spherical agglomerates of 10-phenothiazinylpropanoic acid is characterized by stirring a suspension of 10-phenothiazinylpropanoic acid in water in the presence of a binder liquid which is not miscible with water selected from esters of aliphatic or cycloaliphatic acids, aliphatic or cycloaliphatic alcohols, and aliphatic or cycloaliphatic ketones.

Abstract: Phenothiazines of the formula: ##STR1## where R.sub.1 is H or --COOR, where R is selected from the group consisting of branched or unbranched alkyl groups containing from 1 to 4 carbon atoms, and where X is selected from H, branched or unbranched alkyl groups containing from 1 to 4 carbons, and halogen, and pharmaceutically acceptable salts thereof. Particularly preferred phenothiazines are those wherein X is hydrogen, chloro, bromo or methyl, R.sub.1 is COOR, and R is methyl, ethyl or t-butyl.

Abstract: The present invention relates to plastics comprising a high molecular weight, sterically hindered amine, wherein the sterically hindered amine is at least one amine from the group consisting ofI: oligomerized 2,2,4,4-tetramethyl-20(oxiranylmethyl)-7-oxa-3,20-diazadispiro?5.1.11.2!he neicosan-21-one,II: condensation product of 2-chloro-4,6-di(4-n-butylamino-1,2,2,6,6-pentamethylpiperidyl)-1,3,5-triaz ine and 1,2-bis(3-aminopropylamino)ethane, andIII: condensation product of 1-hydroxyethyl-2,2,6,6-tetramethyl-4-hydroxypiperidine and succinic acid.These plastics exhibit a reduced rate of uptake of sulfur compounds.The invention further relates to shaped articles made from these plastics.

Abstract: A quinuclidine derivative represented by the following general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, which has strong squalene synthase inhibiting activity and is useful as a cholesterol lowering agent without causing side effects. ##STR1## (Symbols in the formula represent the following meanings; R.sub.1 : a hydrogen atom, a halogen atom or a lower alkyl group,R.sub.2 : a hydrogen atom, a hydroxyl group or a lower alkoxy group,. . : a single bond or a double bond, with the proviso thatR.sub.2 does not exist when . . . is a double bond,X and Y: the same or different from each other and each represents a bond, an oxygen atom (--O--), a carbonyl group (--CO--), a group represented by the formula --S(O).sub.p -- or a group represented by the formula --NR.sub.3 --,p: 0, 1 or 2,R.sub.3 : a hydrogen atom or a lower alkyl group which may have a substituent,A: a saturated or unsaturated lower alkylene group, a group of the formula --(CH.sub.2).sub.m Z(CH.sub.

Abstract: Aliphatic hydrocarbyl-substituted aromatic amines are prepared by reacting an aromatic amine and an aliphatic hydrocarbylating agent, such as an olefin, in the presence of a heteropolyacid catalyst such as Cs.sub.2.5 H.sub.0.5 PW.sub.12 O.sub.40, for a period of time and at a temperature sufficient to permit reaction.

Abstract: There are described compounds of the formula ##STR1## Wherein the variables have been defined herein. The compounds are useful as research tools in the determination of biologically active peptides sequences and also potentially suitable as medicaments, some of them being useful in the prevention or control of the formation of blood platelet thrombi, and some compounds are useful as intermediates.

Abstract: There are described compounds of the formula ##STR1## Wherein the variables have been defined herein. The compounds are useful as research tools in the determination of biologically active peptides sequences and also potentially suitable as medicaments, some of them being useful in the prevention or control of the formation of blood platelet thrombi, and some compounds are useful as intermediates.

Abstract: The invention relates to pyrrolidine monomeric units and to oligomers which are joined via phosphate linkages, including phosphorothioate, phosphodiester and phosphoramidate linkages.

Abstract: A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.sup.1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R.sup.2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R.sup.3 represents a group of the formula, ##STR2## (R.sup.4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

Abstract: New benzothiazine derivatives corresponding to the general formula I: ##STR1## in which: X represents halogen,n represents 0, 1, or 2,B represents the following formula: ##STR2## in which: R.sub.1 & R.sub.2 together with the carbons to which they are attached form a 6-carbon-atom aromatic ring which is optionally substituted by a group X' representing halogen, andY represents the radical --(SO.sub.2).sub.x --Alk--Z, x, Alk, and Z are as defined in the specification;as well as their possible stereoisomers, epimers, N-oxides and pharmaceutically-acceptable acid or base addition salts; and medicinal products containing the same, useful in the treatment of inflammatory disorders requiring an inhibitor of cytokines.

Abstract: Novel pyrrolidine monomers bearing various functional groups are used to prepare oligomeric structures. The pyrrolidine monomers can be joined via standard phosphate linkages including phosphodiester and phosphorothioate linkages. Useful functional groups include nucleobases as well as polar groups, hydrophobic groups, ionic groups, aromatic groups and/or groups that participate in hydrogen-bonding.

Abstract: The invention relates to reaction products suitable as antioxidants which are substantially liquid at room temperature and which are obtained by the reaction of olefins with mixtures of diphenylamines and phenothiazines which may be alkylated. These products are obtainable by reacting an olefin of formulaR.sub.1 R.sub.2 C.dbd.CHR.sub.3 (I)with a mixture of compounds of formulae II and III ##STR1## in the presence of an acid catalyst, wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.25 alkyl or phenyl,R.sub.2 is C.sub.1 -C.sub.25 alkyl, benzyl or phenyl,R.sub.3 is hydrogen or C.sub.1 -C.sub.12 alkyl,R.sub.4, R*.sub.4, R.sub.5 and R*.sub.5 are each independently of one another hydrogen, C.sub.1 -C.sub.25 alkyl, C.sub.5 -C.sub.12 cycloalkyl, benzyl, .alpha.-methylbenzyl or .alpha.,.alpha.-dimethylbenzyl, and R.sub.6 and R*.sub.6 are each independently of the other hydrogen, C.sub.1 -C.sub.18 alkyl, C.sub.1 -C.sub.4 alkenyl, benzyl or a radical of formula --CH(R.sub.9)--CH(R.sub.10)--S--R.sub.11, andR.sub.7 and R.sub.

Abstract: Disclosed is an electrode suitable for the electrochemical regeneration of the co-enzymes NADH and NADPH. The electrode has imparted on its surface a mediator function which is a 3-methylene-3H-phenothiazine or a 3-methylene-3H-phenoxazine compound.

Abstract: An insecticidal composition containing a guanidine derivative of the formula: ##STR1## wherein R.sup.1 is an optionally substituted homocyclic or heterocyclic group, n is 0 or 1, R.sup.2 is a hydrogen atom or an optionally substituted hydrocarbon group, R.sup.3 is a primary, secondary or tertiary amino group, X is an electron attractive group such as nitro or trifluoroacetyl group, provided that when n is 0, R.sup.1 is an optionally substituted heterocyclic group or a salt thereof.

Abstract: A mixture containing phenothiazines which is obtainable by reacting a mixture of diphenylamines comprising______________________________________ 1 to 5% by weight of a) diphenylamine 8 to 18% by weight of b) 4-tert-butyldiphenylamine 21 to 31% by weight of c) one or more compounds selected from i) 4-tert-octyldiphenylamine ii) 4,4'-di-tert-butyldiphenylamine iii) 2,4,4'-tris-tert-butyldiphenylamine 20 to 31% by weight of d) one or more compounds selected from i) 4-tert-butyl-4'-tert-octyldiphenylamine ii) 2,2'- or 2,4'-di-tert- octyldiphenylamine iii) 2,4-di-tert-butyl-4'-tert- octyldiphenylamine, and 15 to 29% by weight of e) the compound i) 4,4'-di-tert-octyldiphenylamine, or the compounds i) 4,4'-di-tert-octyldiphenylamine and ii) 2,4-di-tert-octyl-4'-tert- butyldiphenylamine, ______________________________________with 1 to 200 mol % of elemental sulfur, in the presence of 0.

Abstract: A process for the direct and regioselective functionalization of phenothiazine which allows one to introduce an SH group in position 2, said process comprising the sulfination or sulfonation of the phenothiazine N-protected with an alkoxycarbonyl, an alkylsulfonyl or an arylsulfonyl group, the reduction of the produce obtained to give the N-protected 2-mercapto-phenothiazine, and the deprotection of the nitrogen atom. The thus-obtained 2-mercapto-phenothiazine is an important intermediate for the preparation of pharmacological active compounds.

Abstract: A novel prolinal derivative of the general formula: ##STR1## [wherein A represents alkylene or alkenylene group of from 1 to 8 carbon atom(s) or a saturated hydrocarbon ring of from 3 to 7 carbon atoms, R represents hydrogen atom, phenyl group, benzyl group, alkyl group of from 1 to 8 carbon atom(s) or cycloalkyl group of from 3 to 7 carbon atoms,B represents alkylene group of from 1 to 8 atom(s) unsubstituted or substituted by phenyl group or benzyl group, or a single bond,D represents carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three of halogen atom, alkyl or alkoxy group of from 1 to 4 carbon atom(s), nitro group or trifluoromethyl group.]possess inhibitory activity on prolyl endopeptidase, and therefore are useful for treating and/or preventing agent as a amnesia.

Abstract: This application describes 3-arylalkyl esters of 4,5-dihydro-9,10-dioxo-2-anthracenecarboxylic acid and a process for making them. Also described is a method of using the compounds in the treatment of arthritis.

Abstract: A novel prolinal derivative of general formula: ##STR1## [wherein A represents a group of the general formula: ##STR2## (wherein one of R.sup.1 and R.sup.2 represents hydrogen atom and the other represents alkyl group of from 2 to 5 carbon atoms, alkoxy group of from 1 to 5 carbon atom(s), phenyl group, benzyl group, cycloalkyl group of from 4 to 6 carbon atoms or (cycloalkyl group of from 4 to 6 carbon atoms)--methyl group or R.sup.1 and R.sup.2 each represents, same or different, alkyl group of from 1 to 4 carbon atom(s).) or a group of the general formula: ##STR3## (wherein m represents an integer of from 3 to 6.) n represents an integer of from 3 to 10.D represents carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three of halogen atom, nitro group, trifluoromethyl group, alkyl or alkoxy group of from 1 to 4 carbon atom(s).]possess inhibitory activity on prolyl endopeptidase, and therefore be useful for treating and/or preventing agent for amnesia.

Abstract: A process for stabilizing an ethylenically unsaturated monomer or oligomer from premature polymerization is disclosed whereby a stabilizing amount of an amine, preferably a substituted hindered amine, in combination with phenothiazine or other related heterocyclic moiety is added to said polymerizable monomer or oligomer. The ethylenically unsaturated monomer or oligomer encompass vinyl monomers or oligomers bearing at least one polymerizable moiety. The combination of substituted hindered amine plus phenothiazine inhibits premature polymerization in the liquid and/or vapor phase.

Abstract: An ammonium salt of an alkenylsuccinic half-amide of formula (I) below ##STR1## in which R.sup.1 denotes H or a C.sub.6 -C.sub.18 -alkenyl radical, provided that the radicals R.sup.1 are not both H or both C.sub.6 -C.sub.18 -alkenyl,X denotes a group of the formula --NHR.sup.2 or --NR.sup.2 R.sup.3, in whichR.sup.2 and R.sup.3 denote C.sub.1 -C.sub.6 -alkyl, cycloalkyl or a heterocyclic ring attached to the nitrogen atom via an alkylene chain,andA denotes XH or a different primary, secondary, or tertiary amine, for example an alkanolamine or a polyamine,and the use thereof as a corrosion inhibitor in oil and/or gas production technology.

Abstract: A melt transesterification process for the production of polycarbonates, wherein at least one bis(aryl)carbonate is reacted with at least one dihydric phenol in the melted state, in the presence of a transesterification catalyst comprising at least one heterocyclic borate salt of the formula:M.sup.+ B(R).sub.n (A).sup.-.sub.4-n (I)where M.sup.+ is an alkali metal, tetra-alkylammonium, tetra-arylammonium, tetra-alkylphosphonium and tetra-arylphosphonium ion; R is H, alkyl, aryl or aralkyl; n is an integer from 0-3; and A is an aromatic or aliphatic heterocyclic ring.

Abstract: A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), [wherein R1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R3 represents a group of the formula, (R4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group, m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.